KMPH
$0.60
Kempharm
($.01)
(1.82%)
KMPH
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.05)
Revenue:  $1.90 Mil
Thursday
Oct 29
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Wednesday, August 12, 2020

What do you expect when KMPH reports earnings?
Beat
Meet
Miss

Where is KMPH's stock price going from here?
Up
Flat
Down
Stock chart of KMPH
Analysts
Summary of analysts' recommendations for KMPH
Score
Grade
Pivots
Resistance
$0.68
$0.65
$0.63

$0.60

Support
$0.58
$0.55
$0.53
Tweet
Growth
Description
KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States.